This new report by Medtech Insight includes analyses of products, technologies, current and forecast markets, competitors, and opportunities in the European skin replacements and substitutes and active wound repair modulators market. Major topics covered by this report include an overview of the healthcare markets of France, Germany, Italy, Spain, and the United Kingdom; an overview of clinical issues in wound management; skin replacement and substitutes including allografts, autografts, xenografts, amniotic membranes, and autologous and tissue-engineered skin replacements and substitutes (e.g., epidermal, dermal, and composite bilayer skin equivalents); and active wound repair modulators including topical antimicrobials, growth factors, gene therapy agents, antibiotics/anti-infectives, hormones, matrix metalloproteinase enzyme inhibitors, neuropeptides, and stem cells.
EXECUTIVE SUMMARY i. Clinical Issues in Wound Management ii. Skin Replacements and Substitutes a. Allografts b. Autografts c. Xenografts d. Amniotic Membranes e. Skin Equivalents f. Skin Replacements and Substitutes, Market Analysis iii. Active Wound Repair Modulators a. Topical Antimicrobial Products b. Growth Factors c. Other Active Wound Repair Modulators d. Active Wound Repair Modulators, Market Analysis iv. Combined Market Analysis a. Market Drivers b. Market Limiters c. Combined Market Forecast Exhibit ES-1: Europe, Skin Replacements and Substitutes, Market Forecast, by Country, 2008-2013 Exhibit ES-2: Europe, Active Wound Repair Modulators, Market Forecast, by Country, 2008-2013 Exhibit ES-3: Europe, Skin Replacements and Substitutes and Active Wound Repair Modulators, Combined Market Forecast, by Country, 2008-2013 1. EUROPEAN HEALTHCARE MARKETS 1.1 The European Union 1.1.1 A Common Currency 1.1.2 Regulatory Policies 1.1.3 Reimbursement 1.1.4 Healthcare Spending 1.2 Selected European National Healthcare Profiles 1.2.1 France 18.104.22.168 Healthcare Organization and Reform 22.214.171.124 Hospital Services 126.96.36.199 Medical Device Reimbursement 1.2.2 Germany 188.8.131.52 Healthcare Organization and Reform 184.108.40.206 Hospital Services 220.127.116.11 Medical Device Reimbursement 1.2.3 Italy 18.104.22.168 Healthcare Organization and Reform 22.214.171.124 Hospital Services 126.96.36.199 Medical Device Reimbursement 1.2.4 Spain 188.8.131.52 Healthcare Organization and Reform 184.108.40.206 Hospital Services 220.127.116.11 Medical Device Reimbursement 1.2.5 United Kingdom 18.104.22.168 Healthcare Organization and Reform 22.214.171.124 Hospital Services 126.96.36.199 Medical Device Reimbursement Exhibit 1-1: European Union, Medical Devices Risk Classification System Exhibit 1-2: European Union Population Statistics Comparison for the Years 1999, 2009, and 2019 Exhibit 1-3: France, Selected National Healthcare Statistics Exhibit 1-4: Germany, Selected National Healthcare Statistics Exhibit 1-5: Italy, Selected National Healthcare Statistics Exhibit 1-6: Spain, Selected National Healthcare Statistics Exhibit 1-7: United Kingdom, Selected National Healthcare Statistics 2. CLINICAL ISSUES IN WOUND MANAGEMENT 2.1 Physiology of Wound Closure 2.1.1 Layers of the Skin and Supporting Structures 188.8.131.52 Epidermis 184.108.40.206 Dermis 220.127.116.11 Subcutaneous Tissue 18.104.22.168 Fascia 22.214.171.124 Muscle 126.96.36.199 Bone 2.1.2 Wound Closure Process 188.8.131.52 Hemostasis 184.108.40.206 Inflammation 220.127.116.11 Proliferation 18.104.22.168 Remodeling Phase 2.2 Factors Affecting Wound Closure 2.2.1 Extrinsic Factors 22.214.171.124 Desiccation 126.96.36.199 Hydration 188.8.131.52 Infection 184.108.40.206 Maceration 220.127.116.11 Medication and Other Treatment Modalities 18.104.22.168 Necrotic Tissue and Debris 22.214.171.124 Oxygenation 126.96.36.199 Stress 188.8.131.52 Temperature 184.108.40.206 Wound Creation and Depth 220.127.116.11 Wound Closure Techniques 18.104.22.168 Other Extrinsic Factors 2.2.2 Intrinsic Factors 22.214.171.124 Body Build 126.96.36.199 Chronic Illness and Age 188.8.131.52 Nutrition 2.2.3 Complications of Wound Healing 184.108.40.206 Bleeding 220.127.116.11 Scarring 2.3 Major Wound Types 2.3.1 Amputation 2.3.2 Arterial Ulcers 2.3.3 Burns 2.3.4 Diabetic Ulcers 2.3.5 Pressure Ulcers 2.3.6 Surgical Wounds 2.3.7 Traumatic Wounds 2.3.8 Venous Ulcers Exhibit 2-1: The Skin's Layers and Supporting Structures Exhibit 2-2: Phases of the Wound Closure Process Exhibit 2-3: Extrinsic and Intrinsic Factors Affecting Wound Closure Exhibit 2-4: Major Wound Types, by Cause Exhibit 2-5: Stages of Burn Wounds Exhibit 2-6: Stages of Pressure Ulcers Exhibit 2-7: 2008, Europe, Surgical Procedure Volumes, by Type 3. SKIN REPLACEMENTS AND SUBSTITUTES MARKET 3.1 Allografts 3.2 Autografts 3.3 Xenografts 3.4 Amniotic Membranes 3.5 Autologous and Tissue-Engineered Skin Replacements and Substitutes 3.5.1 Epidermal Equivalents 3.5.2 Dermal Equivalents 3.5.3 Composite Bilayer Skin Equivalents 3.6 Skin Substitute Products under Development 3.6.1 Advanced BioHealing 3.6.2 Healthpoint/DFB Pharmaceuticals 3.6.3 Organogenesis 3.6.4 Dr. Suwelack Skin & Health Care 3.7 Market Analysis 3.8 Competitive Analysis Exhibit 3-1: Advantages and Disadvantages of Allografts Exhibit 3-2: 2010, Selected Epidermal Equivalent Skin Substitutes Exhibit 3-3: 2010, Selected Dermal Equivalent Skin Substitutes Exhibit 3-4: 2010, Selected Composite Bilayer Equivalent Skin Substitutes Exhibit 3-5: Europe, Skin Replacements and Substitutes, Market Forecast, by Country, 2008-2013 Exhibit 3-6: 2009, Europe, Skin Replacements and Substitutes Market, Share by Supplier 4. ACTIVE WOUND REPAIR MODULATORS MARKET 4.1 Topical Antimicrobials 4.1.1 Products 4.1.2 Market Analysis 4.1.3 Competitive Analysis 4.2 Growth Factors 4.2.1 Classification of Growth Factors 18.104.22.168 Fibroblast Growth Factors 22.214.171.124 Transforming Growth Factors 126.96.36.199 Epidermal Growth Factors 188.8.131.52 Platelet-Derived Growth Factors 184.108.40.206 Insulin-Like Growth Factors 220.127.116.11 Keratinocyte Growth Factors 18.104.22.168 Vascular Endothelial Growth Factors 22.214.171.124 Autologous Growth Factors 126.96.36.199.1 Arteriocyte Medical Systems 188.8.131.52.2 Cytomedix 184.108.40.206.3 Harvest Technologies 220.127.116.11 Angiogenic Growth Factors 4.2.2 Products 4.2.3 Market Analysis 4.3 Gene Therapy Agents 4.4 Other Active Wound Repair Modulators 4.4.1 Antibiotics and Anti-Infectives 18.104.22.168 Basilea Pharmaceutica 22.214.171.124 Cerexa/Forest Laboratories 126.96.36.199 Cubist Pharmaceuticals 188.8.131.52 Helix BioMedix 184.108.40.206 Theravance 4.4.2 Hormones 4.4.3 Matrix Metalloproteinase Enzyme Inhibitors 220.127.116.11 Dermagenics/Greystone Pharmaceuticals 18.104.22.168 Smith & Nephew 22.214.171.124 Systagenix Wound Management 4.4.4 Neuropeptides in Diabetic Wounds 4.4.5 Stem Cells 4.4.6 Other Products 126.96.36.199 Kingfisher Healthcare 188.8.131.52 Pioneer Surgical Orthobiologics/Pioneer Surgical Technology 184.108.40.206 RegeneRx Biopharmaceuticals Exhibit 4-1: 2010, Selected Topical Antimicrobial Products Exhibit 4-2: Europe, Topical Antimicrobial Products, Market Forecast, by Country, 2008-2013 Exhibit 4-3: 2009, Europe, Topical Antimicrobial Products, Share by Supplier Exhibit 4-4: 2010, Selected Growth Factors in Development for Wound Healing Applications Exhibit 4-5: 2010, Selected Angiogenic Growth Factors Exhibit 4-6: Europe, Growth Factors Used in Wound Healing Applications, Market Forecast, by Country, 2008-2013 5. COMPANY PROFILES 5.1 Advanced BioHealing, Inc. 5.2 Cook Biotech, Inc./Cook Group, Inc. 5.3 Cytomedix, Inc. 5.4 Fidia Advanced Biopolymers SRL/Anika Therapeutics, Inc. 5.5 GlaxoSmithKline PLC 5.6 Integra LifeSciences Corporation 5.7 LEO Pharma AS/LEO Foundation 5.8 sanofi-aventis 5.9 Smith & Nephew PLC 5.10 Systagenix Wound Management LTD APPENDIX: COMPANY LISTING